Yield10 Competitors
| YTEN Stock | USD 0.01 0.00 0.00% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Yield10 Bioscience competition on your existing holdings.
Yield10 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Yield10 Bioscience's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Yield10 Bioscience Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Yield10 Bioscience and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Yield10 and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Yield10 Bioscience does not affect the price movement of the other competitor.
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Yield10 Stock performing well and Yield10 Bioscience Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Yield10 Bioscience's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| KPLUY | 2.09 | 0.43 | 0.16 | 0.34 | 2.23 | 6.97 | 13.69 | |||
| IPI | 2.09 | 0.22 | 0.07 | 0.03 | 2.49 | 4.29 | 16.60 | |||
| CGA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| BIOX | 3.19 | (0.40) | 0.00 | (2.40) | 0.00 | 8.70 | 26.87 | |||
| MBCF | 0.98 | 0.28 | 0.30 | (2.27) | 0.53 | 2.86 | 12.90 | |||
| VNPKF | 7.24 | 0.87 | 0.07 | (1.29) | 9.52 | 25.49 | 80.31 | |||
| YARIY | 1.42 | 0.15 | 0.11 | 0.11 | 1.89 | 2.74 | 10.57 | |||
| BHIL | 8.60 | (0.29) | 0.00 | (0.22) | 0.00 | 19.50 | 153.37 | |||
| AVD | 2.60 | (0.09) | 0.00 | (0.20) | 0.00 | 4.83 | 15.45 | |||
| LVRO | 3.81 | (0.16) | 0.00 | (0.57) | 0.00 | 8.65 | 27.28 |
Cross Equities Net Income Analysis
Compare Yield10 Bioscience and related stocks such as KS AG DRC, Intrepid Potash, and CGA Old Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPI | 36 M | 109.4 M | 87.4 M | 22.3 M | 9.8 M | (524.8 M) | (66.6 M) | (22.9 M) | 11.8 M | 13.6 M | (27.2 M) | 249.8 M | 72.2 M | (35.7 M) | (212.8 M) | (202.2 M) |
| BIOX | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (1.2 M) | (11.8 M) | (11 M) | (18.4 M) | 3.4 M | (6.9 M) | (7.2 M) | 18.8 M | 3.2 M | (1.2 M) | (1.3 M) |
| BHIL | (43.9 M) | (43.9 M) | (43.9 M) | (43.9 M) | (43.9 M) | (43.9 M) | (43.9 M) | (43.9 M) | (43.9 M) | (43.9 M) | (64.5 M) | (126.2 M) | (127.9 M) | (115.3 M) | (103.8 M) | (109 M) |
| AVD | 1000 K | 22.1 M | 36.9 M | 34.4 M | 4.8 M | 6.6 M | 12.8 M | 20.3 M | 24.2 M | 13.6 M | 15.2 M | 18.6 M | 27.4 M | 7.5 M | 8.6 M | 11.2 M |
| LVRO | (108.7 M) | (108.7 M) | (108.7 M) | (108.7 M) | (108.7 M) | (108.7 M) | (108.7 M) | (108.7 M) | (108.7 M) | (108.7 M) | 38.4 M | 78.2 M | (260.7 M) | (762.5 M) | (686.2 M) | (651.9 M) |
| ICL | (42.4 M) | 1.5 B | 1.3 B | 818.6 M | 463.6 M | 509 M | (122 M) | 364 M | 1.2 B | 475 M | 24 M | 783 M | 2.2 B | 647 M | 407 M | 738.6 M |
| FMC | 152.5 M | 365.9 M | 416.2 M | 293.9 M | 307.5 M | 489 M | 209.1 M | 535.8 M | 502.1 M | 477.4 M | 552.4 M | 739.6 M | 736.5 M | 1.3 B | (2.7 M) | (2.6 M) |
| CF | (74.2 M) | 1.5 B | 1.8 B | 1.5 B | 1.4 B | 699.9 M | (277 M) | 358 M | 290 M | 493 M | 432 M | 1.3 B | 3.3 B | 1.5 B | 1.2 B | 793 M |
| MOS | 111.7 M | 2.5 B | 1.9 B | 1.9 B | 1 B | 1 B | 297.8 M | (107.2 M) | 470 M | (1 B) | 666.1 M | 1.6 B | 3.6 B | 1.2 B | 174.9 M | 166.2 M |
| NTR | 88.9 M | 3.1 B | 2.1 B | 1.8 B | 1.5 B | 1.3 B | 336 M | 327 M | 3.6 B | 992 M | 459 M | 3.2 B | 7.7 B | 1.3 B | 674 M | 1.1 B |
| SMG | (6.9 M) | 106.5 M | 161.1 M | 166.5 M | 159.8 M | 320.3 M | 218.3 M | 63.7 M | 460.7 M | 387.4 M | 512.5 M | (437.5 M) | (380.1 M) | (34.9 M) | (40.1 M) | (38.1 M) |
| CTVA | 503 M | 503 M | 503 M | 503 M | 503 M | 503 M | 503 M | 2.5 B | (5 B) | (270 M) | 681 M | 1.8 B | 1.1 B | 735 M | 907 M | 952.4 M |
Yield10 Bioscience and related stocks such as KS AG DRC, Intrepid Potash, and CGA Old Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Yield10 Bioscience financial statement analysis. It represents the amount of money remaining after all of Yield10 Bioscience operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Yield10 Bioscience Competitive Analysis
The better you understand Yield10 Bioscience competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Yield10 Bioscience's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Yield10 Bioscience's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Yield10 Bioscience Competition Performance Charts
Five steps to successful analysis of Yield10 Bioscience Competition
Yield10 Bioscience's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Yield10 Bioscience in relation to its competition. Yield10 Bioscience's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Yield10 Bioscience in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Yield10 Bioscience's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Yield10 Bioscience, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Yield10 Bioscience position
In addition to having Yield10 Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Pharmaceutical Products Thematic Idea Now
Pharmaceutical Products
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Pharmaceutical Products theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Pharmaceutical Products Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Yield10 Bioscience. If investors know Yield10 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Yield10 Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (20.14) | Revenue Per Share | Quarterly Revenue Growth 4 | Return On Assets | Return On Equity |
The market value of Yield10 Bioscience is measured differently than its book value, which is the value of Yield10 that is recorded on the company's balance sheet. Investors also form their own opinion of Yield10 Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Yield10 Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Yield10 Bioscience's market value can be influenced by many factors that don't directly affect Yield10 Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Yield10 Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Yield10 Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Yield10 Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.